Difluoromethylornithine
Post-solid Organ Transplant
University of Wisconsin, MadisonPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Post-solid Organ Transplant cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TACROLIMUS The Second Hospital of Tangshan | Phase 4 | BBB |
Giapreza University of California, San Francisco | Phase 4 | BBB |
Equine Atg University Hospital, Toulouse | Phase 4 | BB |
Everolimus Novartis Pharmaceuticals | Phase 3 | BB |
Noradrenaline University of California, Los Angeles | Phase 4 | BB |
View all 35 →
Same molecule, other indications
Difluoromethylornithine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →